What is Neurophet's business focus and history?

Neurophet is a publicly listed company based in Seoul, South Korea, founded in 2016 by Jake Junkil Been and Donghyeon Kim. It operates in the Medical - Healthcare Information Services industry, specializing in AI-based neuroimaging analysis solutions for brain disorders. Neurophet has raised significant funding, including a $15 million Series C round in November 2023. The company has 65 employees and offers products like Neurophet AQUA and Neurophet SCALE PET.

Neurophet Corporate Details & Core Services

Neurophet is a South Korean company specializing in AI-based neuroimaging analysis solutions for brain disorders, offering products like Neurophet AQUA and Neurophet SCALE PET.

Neurophet Contact Information & Official Links

Website https://www.neurophet.com
Social  
Email id contact@neurophet.com
Phone number +82 2 6954 7971
Head office address Seoul, , South Korea
Tags AI neuroimaging healthcare radiology brain MRI PET neuroscience medical imaging brain disorders neuroradiologist

What are Neurophet's Key Business Metrics & Stats?

No of employees 65
Founded year 2016
Type public
SAICS CODE 7372
Industry Medical - Healthcare Information Services
Location Seoul, South Korea
Stock Name 380550 (KOSDAQ)
Pricing Strategy Specific pricing details not publicly disclosed
Neurophet 380550 (KOSDAQ) Firmographic Snapshot 2026 2016 Founded Year 65 Global Employees South Korea Headquarters Medical -HealthcareInformationServices Industry Public Type Verified by DexterAgent.ai

How much funding has Neurophet raised to date?

Name Description
Funding Amount USD 20 Billion
Stage Series C
Latest Valuation (USD)
Investors KB Investment, Solidus Investment, Profit Asset Management, Quad Asset Management, Kolon Investment, Xolon Investment, Mirae Asset Securities, IBK, DB Financial Investment, Seoil E&M

What are Neurophet's Core Products?

Name Description
Neurophet AQUA AI-powered brain MRI analysis software that assesses brain atrophy and white matter hyperintensities, aiding in the diagnosis of neurodegenerative diseases such as Alzheimer's and vascular dementia.
Neurophet SCALE PET Software that quantitatively analyzes PET images to measure biomarkers like amyloid beta and tau proteins, supporting the evaluation of Alzheimer's disease.
Neurophet tES/TMS LAB Brain imaging treatment planning software for electric and magnetic brain stimulation, facilitating precise targeting for therapeutic interventions.
Neurophet AQUA AD Software designed to monitor prescription decisions, treatment effects, and side effects of Alzheimer's disease therapies, providing advanced brain imaging analysis capabilities.
Neurophet AQUA MS Multiple sclerosis image analysis software that evaluates brain images to assist in the diagnosis and monitoring of multiple sclerosis.

What are the latest developments at Neurophet?

Date Type Description
Nov, 2023 Funding Neurophet secures 20 billion KRW in Series C funding.
Oct, 2024 Partnership Neurophet partners with Beijing LADO Technology to establish a joint venture in China.
Nov, 2024 Regulatory Approval Neurophet's 'Neurophet AQUA' receives FDA 510(k) clearance for multiple sclerosis analysis.
Nov, 2024 Leadership CTO Donghyeon Kim appointed as Co-CEO alongside Jake Junkil Been.
Feb, 2026 Regulatory Approval Neurophet's 'Neurophet AQUA AD Plus' receives FDA 510(k) clearance.

What industry awards and recognitions has Neurophet received?

Date Type Description
Sep, 2025 Recognition Neurophet's 'Neurophet AQUA AD Plus' selected as an innovative medical technology in South Korea.

Neurophet VS Cortechs.ai VS Quibim VS AINOSTICS VS AMRA Medical VS mediaire : 2026 Comparison

Feature Neurophet Cortechs.ai Quibim AINOSTICS AMRA Medical mediaire
Core Strengths Neurophet AQUA, Neurophet SCALE PET, Neurophet tES/TMS LAB, Neurophet AQUA AD, Neurophet AQUA MS NeuroQuant®, NeuroQuant® MS, NeuroQuant® Brain Tumor, NeuroQuant® ARIA, OnQ™ Prostate, NeuroAlign CT, NeuroQuant® PET QP-Prostate®, QP-Brain®, QP-Liver®, QP-Insights® BR[AI]N®, IQ AMRA® BCP Scan, AMRA® MAsS Scan, AMRA® Profiler 4 mdbrain, mdprostate, mdknee
Founded Year 2016 1996 2015 2018 2010 2018
Stock Name/Ticker 380550 (KOSDAQ)
Type public private private private private private
Global Employees 65 58 100 36 76
Revenue (Annual) $2.2(2024) $7.5 Million(2025) $2.1(2024)   $6.6 Million(2025) $17.2 Million(2024)
Headquarters Seoul, South Korea San Diego, California, United States Valencia, Comunidad Valenciana, Spain Manchester, United Kingdom Linköping, Sweden Berlin, Berlin, Germany
Latest Valuation         $6.7 Million  
LATEST REVENUE (TRILLIONS USD) EMPLOYEE COUNT (THOUSANDS) INNOVATORS VISIONARIES DISRUPTORS GIANTS Cortechs.ai 7.5 | 58 Quibim 2.1 | 100 AMRA Medical 6.6 | 0 mediaire 17.2 | 76 Competitive Landscape 2026 DexterAgent.ai
Name Description
Legal Name Neurophet, Inc.
Cin number
GST number
Registration number 2048657415

Who is in Neurophet's executive leadership team?

Name Designation
CEO Jake Junkil Been
Co-CEO Donghyeon Kim

Where are Neurophet's primary office locations?

City Country
Seoul South Korea

What are the current business signals and market intelligence for Neurophet?

Spending next 3 months Expand U.S. market presence, Enhance AI-based neuroimaging solutions, Strengthen global partnerships
Pain points Need for accurate brain disease diagnostics, Efficient neuroimaging analysis, Monitoring treatment efficacy and side effects
Sales motion Direct sales to healthcare institutions, Partnerships with pharmaceutical companies, Collaborations with research organizations
Buyer Persona Neurologists, Radiologists, Clinical researchers
Type of customer Healthcare institutions, Research organizations, Pharmaceutical companies
Key customer domain Neurology, Radiology, Neuroscience research
Annual ACV Varies based on product and customer size

What is Neurophet's annual revenue history?

Year Revenue (USD)
2022 0.7
2023 1.6
2024 2.2

What are Neurophet's risk management and compliance ratings?

GDPR RIsk No
Privacy Risk No
Company Ratings
Glassdoor Rating

What are Neurophet's business model and service classifications?

Saas No
Offline Stores No
Service No
Ecommerce No
Exporter No
Mobile App No
Retail No
B2B No
B2C No
Manufacturing No
Wholesale No
Importer No
Get Company Intelligence in API
(Price is 0.1 USD/Record - pay as you go)

 

Get Company Intelligence in API
(Price is 0.1 USD/Record - pay as you go)